Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | BRS3 | P32247 | 1/20 | 0.46 |
| ▸ | USP1 | O94782 | 6/20 | 0.38 |
| ▸ | WDR48 | Q8TAF3 | 4/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14567879 | 0.83 | CYP19A1 (0.63) | NOTUMCYP19A1BRS3 | |
| SCHEMBL13527241 | 0.82 | CYP19A1 (0.61) | NOTUMCYP19A1BRS3 | |
| SCHEMBL4966052 | 0.80 | NOTUM (0.50) | NOTUMCYP19A1BRS3KEAP1 | |
| SCHEMBL17297776 | 0.80 | NOTUM (0.62) | NOTUMCYP19A1BRS3USP1WDR48 | |
| SCHEMBL9969482 | 0.79 | NOTUM (0.50) | NOTUMCYP19A1BRS3USP1WDR48 | |
| SCHEMBL6853891 | 0.78 | NOTUM (0.51) | NOTUMCYP19A1BRS3KEAP1 | |
| SCHEMBL4970815 | 0.78 | NOTUM (0.51) | NOTUMCYP19A1BRS3KEAP1 | |
| SCHEMBL21156444 | 0.78 | CYP19A1 (0.74) | NOTUMCYP19A1BRS3KDM5B | |
| SCHEMBL12844428 | 0.78 | CYP19A1 (0.59) | NOTUMCYP19A1BRS3USP1WDR48 | |
| SCHEMBL21157743 | 0.75 | BCHE (0.42) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | NOTUM 3719/4885CYP19A1 709/4885BRS3 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.